Erratum: L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation (Arteriosclerosis, Thrombosis, and Vascular Biology (2010) 30 (283-289) DOI: 10.1161/ATVBAHA.109.200162);L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 2, 2010, Pages 283-289

  Buga, Georgette M ^a   Navab, Mohamad ^a   Imaizumi, Satoshi ^a   Reddy, Srinivasa T ^a   Yekta, Babak ^a   Hough, Greg ^a   Chanslor, Shawn ^a   Anantharamaiah, G M ^b   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

ApoA I mimetic peptides; ApoE null mice; Arachidonic acid metabolism; L 4F; Platelets

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN RECEPTOR; PEPTIDE DERIVATIVE; PEPTIDE L 4F; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; HYPERLIPIDEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; WILD TYPE;

EID: 75149146738     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATV.0b013e3181f595ee     Document Type: Erratum

References (29)

1. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased throm-bogenic potential with cholesterol reduction. Circulation. 1995;92: 3172-3177.
2. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK, Katagiri H, Majima M, Yokode M, Kita T, Narumiya S. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114:784-794.
3. Gawaz M, Langer H, May AE. Platelets in inflammation and athero-genesis. J Clin Invest. 2005;115:3378-3384.
4. Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, Poliakov E, Sun M, Finton PJ, Curtis BR, Chen J, Zhang R, Silverstein RL, Hazen SL. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086-1095.
5. Siegel-Axel D, Daub K, Seizer P, Lindemann S, Gawaz M. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res. 2008;78:8-17.
6. Boudjeltia KZ, Brohee D, Piro P, Nuyens V, Ducobu J, Kherkofs M, Van Antwerpen P, Cauchie P, Remacle C, Vanhaeverbeek M. Monocyte-platelet complexes on CD14/CD16 monocyte subsets: relationship with ApoA-I levels: a preliminary study. Cardiovasc Pathol. 2008;17: 285-288.
7. Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW, Khan S, Mehta JL. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol. 1999;19:378-383.
8. Mehta JL, Chen LY. Reversal by high-density lipoprotein of the effect of oxidized low-density lipoprotein on nitric oxide synthase protein expression in human platelets. J Lab Clin Med. 1996;127:287-295.
9. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res. 2004;95: 764-772.
10. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res. 2008;49: 2302-2311.
11. Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M, Sirtori CR. Increased platelet sensitivity and thromboxane B2 formation in type-II hyperlipoproteinaemic patients. Eur J Clin Invest. 1984;14:329-333.
12. Eynard AR, Tremoli E, Caruso D, Magni F, Sirtori CR, Galli G. Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIA hypercholesterolemic subjects. Atherosclerosis. 1986;60:61-66.
13. Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res. 2002;43:477-485.
14. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res. 2001;42:1096-1104.
15. Ebbe S, Boudreaux MK. Relationship of megakaryocyte ploidy with platelet number and size in cats, dogs, rabbits and mice. J Comp Clin Pathol. 1998;8:250-260.
16. Harrison P, Briggs C, Machin SJ. Platelet counting. Methods Mol Biol. 2004;272:29-46.
17. Tandon NN, Tralka TS, Jamieson GA. Synergistic effects of butyrate on platelet responses to arachidonate, A23187, PGE1, and forskolin. Blood. 1986;67:366-372.
18. Chen H, Yu QS, Guo ZG. High density lipoproteins enhanced antiaggre-gating activity of nitric oxide derived from bovine aortal endothelial cells. Sheng Li Xue Bao. 2000;52:81-84.
19. Sullam PM, Valone FH, Mills J. Mechanisms of platelet aggregation by viridans group streptococci [published correction appears in Infect Immun. 1987;55:2864]. Infect Immun. 1987;55:1743-1750.
20. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes. 2003;52: 1248-1255.
21. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM. Oral D-4F causes formation of pre-/3 high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:3215-3220.
22. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290-292.
23. Bills TK, Smith JB, Silver MJ. Selective release of archidonic acid from the phospholipids of human platelets in response to thrombin. J Clin Invest. 1977;60:1-6.
24. Best LC, McGuire MB, Martin TJ, Preston FE, Russell RGG. Effects of epoxymethano analogues of prostaglandin endoperoxides on aggregation, on release of 5-hydroxytryptamine and on the metabolism of 3',5'-cyclic AMP and cyclic GMP in human platelets. Biochim Biophys Acta. 1979; 583:344-351.
25. Chevy F, Wolf C, Colard O. A unique pool of free arachidonate serves as substrate for both cyclooxygenase and lipoxygenase in platelets. Lipids. 1991;26:1080-1085.
26. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. Structure and function of HDL mimetics [published online ahead of print 2009]. Arterioscler Thromb Vasc Biol. 2009 July 16 [Epub ahead of print].
27. Shankar H, Kahner BN, Prabhakar J, Lakhani P, Kim S, Kunapuli SP. G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood. 2006;108:3027-3034.
28. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115: 3355-3362.
29. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1979;30:293-331.